@article{057116478,
title = "In 2016, everolimus was approved by Health Canada for the treatment of unresectable, locally advanced or metastatic, well-differentiated, non-functional, neuroendocrine tumours (NET) of gastrointestinal (GI) or lung origin in adult patients with progressive disease. This analysis evaluated the cost-effectiveness of everolimus in this setting from a Canadian societal perspective. A partitioned survival model was developed to compare the cost per life-year (LY) gained and cost per quality-adjusted",
author = "Chua, A. and Perrin, A. and Ricci, J.F. and Neary, M.P. and Thabane, M.",
year = "2018",
journal = "Current Oncology",
volume = "25",
number = "1",
pages = "32-40",
issn = "1198-0052",
doi = "10.3747/co.25.3532",
url = "https://eurekamag.com/research/057/116/057116478.php"
}